1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options

 
• By Jessica Merrill

The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.

horse race
Iveric and Apellis are racing to compete in geographic atrophy • Source: Shutterstock

Despite advances in the treatment of wet age-related macular degeneration (AMD), no drugs are approved by the US Food and Drug Administration for geographic atrophy (GA), the most advanced stage of wet AMD. That could change soon, however, and Iveric Bio hopes to be one of the first to bring a drug for GA to the market, though it will likely be behind Apellis Pharmaceuticals, Inc..

Iveric announced positive Phase III data from the second of two Phase III clinical studies testing the complement C5 inhibitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.